Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
- PMID: 25301630
- PMCID: PMC4636050
- DOI: 10.1126/science.1253462
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Abstract
Spatial and temporal dissection of the genomic changes occurring during the evolution of human non-small cell lung cancer (NSCLC) may help elucidate the basis for its dismal prognosis. We sequenced 25 spatially distinct regions from seven operable NSCLCs and found evidence of branched evolution, with driver mutations arising before and after subclonal diversification. There was pronounced intratumor heterogeneity in copy number alterations, translocations, and mutations associated with APOBEC cytidine deaminase activity. Despite maintained carcinogen exposure, tumors from smokers showed a relative decrease in smoking-related mutations over time, accompanied by an increase in APOBEC-associated mutations. In tumors from former smokers, genome-doubling occurred within a smoking-signature context before subclonal diversification, which suggested that a long period of tumor latency had preceded clinical detection. The regionally separated driver mutations, coupled with the relentless and heterogeneous nature of the genome instability processes, are likely to confound treatment success in NSCLC.
Copyright © 2014, American Association for the Advancement of Science.
Figures
Comment in
-
Cancer. Attack of the clones.Science. 2014 Oct 10;346(6206):169-70. doi: 10.1126/science.1259926. Science. 2014. PMID: 25301605 No abstract available.
-
Lung cancer: Heterogeneity in space and time.Nat Rev Clin Oncol. 2014 Dec;11(12):684. doi: 10.1038/nrclinonc.2014.186. Epub 2014 Oct 28. Nat Rev Clin Oncol. 2014. PMID: 25348786 No abstract available.
-
Tumour evolution: clonal ancestry in lung cancer.Nat Rev Cancer. 2014 Dec;14(12):763. doi: 10.1038/nrc3867. Nat Rev Cancer. 2014. PMID: 25568921 No abstract available.
Similar articles
-
Tracking the Evolution of Non-Small-Cell Lung Cancer.N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26. N Engl J Med. 2017. PMID: 28445112
-
Lung cancer: Heterogeneity in space and time.Nat Rev Clin Oncol. 2014 Dec;11(12):684. doi: 10.1038/nrclinonc.2014.186. Epub 2014 Oct 28. Nat Rev Clin Oncol. 2014. PMID: 25348786 No abstract available.
-
Cancer. Attack of the clones.Science. 2014 Oct 10;346(6206):169-70. doi: 10.1126/science.1259926. Science. 2014. PMID: 25301605 No abstract available.
-
Generation of Genomic Alteration from Cytidine Deamination.Adv Exp Med Biol. 2018;1044:49-64. doi: 10.1007/978-981-13-0593-1_5. Adv Exp Med Biol. 2018. PMID: 29956291 Review.
-
APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.Cancer Discov. 2015 Jul;5(7):704-12. doi: 10.1158/2159-8290.CD-15-0344. Epub 2015 Jun 19. Cancer Discov. 2015. PMID: 26091828 Free PMC article. Review.
Cited by
-
Treatment and Prevention of Lung Cancer Using a Virus-Infected Reprogrammed Somatic Cell-Derived Tumor Cell Vaccination (VIReST) Regime.Front Immunol. 2020 Aug 13;11:1996. doi: 10.3389/fimmu.2020.01996. eCollection 2020. Front Immunol. 2020. PMID: 32903551 Free PMC article.
-
Heterogeneity of Cancer Stem Cells: Rationale for _targeting the Stem Cell Niche.Biochim Biophys Acta. 2016 Dec;1866(2):276-289. doi: 10.1016/j.bbcan.2016.10.003. Epub 2016 Oct 15. Biochim Biophys Acta. 2016. PMID: 27751894 Free PMC article. Review.
-
Urinary Biomarkers for Early Diagnosis of Lung Cancer.J Clin Med. 2021 Apr 16;10(8):1723. doi: 10.3390/jcm10081723. J Clin Med. 2021. PMID: 33923502 Free PMC article.
-
Molecular features of tumor-derived genetic alterations in circulating cell-free DNA in virtue of autopsy analysis.Sci Rep. 2021 Apr 16;11(1):8398. doi: 10.1038/s41598-021-87094-1. Sci Rep. 2021. PMID: 33863951 Free PMC article.
-
Genomic Landscape of NSCLC in the Republic of Ireland.JTO Clin Res Rep. 2023 Dec 27;5(2):100627. doi: 10.1016/j.jtocrr.2023.100627. eCollection 2024 Feb. JTO Clin Res Rep. 2023. PMID: 38333230 Free PMC article.
References
-
- World Health Organization 2013 www.who.int/cancer/en/
-
- Siegel R, Naishadham D, Jemal A. CA Cancer J. Clin. 2013;63:11–30. - PubMed
-
- Tanaka H, et al. Cancer Res. 2007;67:6007–6011. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- A4688/CRUK_/Cancer Research UK/United Kingdom
- 091730/WT_/Wellcome Trust/United Kingdom
- 18377/CRUK_/Cancer Research UK/United Kingdom
- 105104/WT_/Wellcome Trust/United Kingdom
- 088340/WT_/Wellcome Trust/United Kingdom
- 17001/CRUK_/Cancer Research UK/United Kingdom
- A19310/CRUK_/Cancer Research UK/United Kingdom
- G0902275/MRC_/Medical Research Council/United Kingdom
- WT_/Wellcome Trust/United Kingdom
- 17786/CRUK_/Cancer Research UK/United Kingdom
- A11590/CRUK_/Cancer Research UK/United Kingdom
- A17786/CRUK_/Cancer Research UK/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical